Key Takeaways
- Apple (AAPL) issued a cautious outlook for the June quarter, projecting gross margins between 47.5% and 48.5% while warning of substantial rises in memory costs and supply constraints for Mac models.
- ANZ Group (ANZ) reported a half-year cash profit of A$3.78 billion, surpassing analyst estimates of A$3.69 billion, and maintained a steady interim dividend of A$0.83 per share.
- Rivian (RIVN) management warned that vehicle launch complexity and supply chain risks will weigh on gross profits through Q2 and Q3, despite rising demand for electric vans.
- AstraZeneca (AZN) received a major regulatory boost as an FDA Advisory Committee voted 7-1 in favor of recommending Truqap for the treatment of PTEN-deficient prostate cancer.
- New Zealand’s consumer confidence plummeted 12.0% month-on-month in April, with the ANZ Consumer Confidence Index dropping to 80.3, signaling deepening economic pessimism.
Apple Navigates Supply Constraints and Capital Shifts
Apple (AAPL) CEO Tim Cook informed investors that the company anticipates a substantial rise in memory costs during the June quarter. The tech giant also expects supply constraints to center primarily on several Mac models, which may impact near-term availability.
In a significant shift in financial strategy, the Apple CFO announced that the company is no longer providing a net-cash neutral capital allocation target. Despite this change, the company remains committed to its US advanced manufacturing program, intending to reinvest any recovered funds from tariff refunds back into domestic production.
ANZ Group Delivers Resilient Half-Year Results
ANZ Group (ANZ) posted a half-year cash profit of A$3.78 billion, beating the A$3.69 billion expected by markets. While the Cash Net Interest Margin (NIM) of 1.53% slightly missed the 1.55% estimate, the bank noted that the impact of the "current crisis" on its credit and liquidity positions has been minimal.
The bank's CET1 ratio stood at 12.4%, and it proposed an interim dividend of 83 Australian cents. ANZ intends to fund this dividend by purchasing ordinary shares on-market, reflecting a stable capital position despite lifting its collective provisions.
Rivian Faces Margin Pressure Amid Launch Complexity
Rivian (RIVN) CFO Claire McDonough warned that the complexity of new vehicle launches will weigh on automotive gross profit in the second and third quarters. The company is actively working to mitigate supply chain risks and elevated costs driven by macroeconomic and geopolitical factors.
On the demand side, CEO RJ Scaringe noted that demand for electric vans continues to rise. The company is also seeing an increase in trade-ins of gasoline vehicles, though it remains wary of potential IEEPA tariff impacts in future quarters.
Healthcare and Market Infrastructure Developments
AstraZeneca (AZN) shares are in focus after an FDA Advisory Committee recommended the combination treatment Truqap for PTEN-deficient prostate cancer. The 7-1 favorable vote marks a critical step toward full regulatory approval for the oncology drug.
In market infrastructure news, S&P Global (SPGI) is reportedly considering new index rules to speed up the addition of mega IPOs to its benchmarks. This move follows a period of significant large-scale listings that have historically faced long waiting periods for index inclusion.
Geopolitical Tensions and Macroeconomic Slump
Geopolitical risks remain elevated as Mercuria filed a lawsuit against the Baltic Exchange over a shipping gauge impacted by the Hormuz incident. Meanwhile, Iran’s Foreign Ministry cautioned that it is "unrealistic" to expect swift results from ongoing talks with the United States.
In the South Pacific, New Zealand's economic outlook darkened as consumer confidence fell 12.0% in April. The ANZ Consumer Confidence Index now sits at 80.3, down from 91.3, as households grapple with persistent inflation and high interest rates.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.